Meeting
2020 ASCO Virtual Scientific Program
Lenalidomide plus R-GDP (R2-GDP) in relapsed/refractory diffuse large B-cell lymphoma: Final results of the R2-GDP-GOTEL trial.
Authors
Luis De La Cruz Merino Sr.
Clinical Oncology Department, Hospital Universitario Virgen Macarena, Seville, Spain
Luis De La Cruz Merino Sr., Alejandro Martin Sr., Esteban Nogales Fernández , Fernando Carnicero González , Eduardo Ríos Herranz , Fátima de la Cruz-Vicente , Guillermo Rodriguez , Concepción Nicolás , Natividad Martinez-Banaclocha , Josep Guma , Jose Gómez-Codina , Antonio Salar Silvestre , Delvys Rodriguez-Abreu , Christina Quero Blanco , Jorge Labrador Gómez , Maria Guirado , Natalia Palazón-Carrión , Pablo Espejo García , Mariano Provencio-Pulla , Antonio Rueda Dominguez
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
EudraCT 2014-001620-29
Citation
J Clin Oncol 38: 2020 (suppl; abstr 8019)
DOI
10.1200/JCO.2020.38.15_suppl.8019
Abstract #
8019
Poster Bd #
352
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Epcoritamab (epco) with gemcitabine + oxaliplatin (GemOx) in patients (pts) with relapsed or refractory (R/R) diffuse large B‑cell lymphoma (DLBCL) ineligible for autologous stem cell transplant (ASCT) induces high response rate even in pts failing CAR T therapy.
First Author: Joshua Brody
Poster
2021 ASCO Annual Meeting
Brentuximab vedotin in combination with lenalidomide and rituximab in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) (Trials in Progress).
First Author: Nancy L. Bartlett
Poster
2021 ASCO Annual Meeting
A phase III trial evaluating glofitamab in combination with gemcitabine plus oxaliplatin versus rituximab in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
First Author: Mark Hertzberg
Poster
2018 ASCO Annual Meeting
Lenalidomide with R-IMED (rituximab, ifosfamide, methotrexate, etoposide and dexamethasone) in refractory or relapsed non-GCB diffuse large B-cell lymphoma: A phase II clinical trial.
First Author: Tongyu Lin